iProXProteomicsXiaohui LiuHomo Sapienshttp://www.iprox.org/page/project.html?id=IPX0006709000liuxiaohui@fudan.edu.cnInstitutes of Biomedical Sciences, Fudan UniversityiProXCarcinomas, chronic hepatitis B infection, Chronic Hepatitis B, Carcinoma, hepatitis B, Liver, Adult Liver Cancers, Hepatocellular carcinoma, Liver Cancer, Hepatoma, Blood, serum hepatitis, adult primary hepatocellular carcinoma, Liver Cancers, Cell Carcinoma, Hepatitis B Virus Infection, Liver Cell, Cancers, adult hepatoma, Blood Serum, Serum, Adult, Hepatomas, Liver Cell Carcinoma, chronic, chronic hepatitis B, Cell Carcinomas, Chronic Hepatitis B Virus Infection, HCC, Liver Cell Carcinomas, Hepatocellular Carcinoma., chronic Hepatitis B, Hepatocellular, Adult Liver Cancer, Chronic, hepatitis B infection, Adult Liver, Hepatocellular Carcinomas, chronic hepatitis B virus infection, Serums, CHB, CancerDisease of liver, Biological Markers, Viral Marker, Antemortem Diagnosis, Surrogate Endpoints, single-organism developmental process, Liver Dysfunction, Liver fibrosis, Laboratory, Liver disorder in pregnancy NOS (disorder), Blood, postnatal development, Biochemical, Metabonomic, Infestations and Infections, Endpoint, Metabonomics, growth and development, adult hepatoma, protein, Serum, Tumor, Hepatomas, Diagnosis, liver disease or disorder, Liver Cell Carcinoma, AI451642, BANK, Techniques, Laboratory Markers, Donor Artificial Insemination, Readability, Chronic Hepatitis B Virus Infection, primary metabolites, Method, Biological, GRP1, CDA2, Grp1, symptoms, hepatic disorder, hepatitis B infection, Transfer, Fs(3)Hor, Liver cirrhosis, Donor Artificial, hepatic disease, treatment, hepatitis B, DRCTNNB1A, DmelCG2684, Liver disorder in pregnancy (disorder), Machine, PTPSTEP, Liver Fibrosis, [X]Diseases of the liver (disorder), serum hepatitis, iecur, adult primary hepatocellular carcinoma, HLD5, proteins, procedures, Adult, NTef2, disease of the liver (disorder), Liver Disorder, SURGICAL AND MEDICAL PROCEDURES, disorder of liver, disease of liver, Hepatocellular Carcinoma, allergic reaction, Immune, hepatitis C virus HCV, Markers, Methodological Studies, Hepatopathy, malignant neoplasm, l(2)k08110, Viral Markers, chronic Hepatitis B, disease management, Therapies, Malignancies, Infections and Infestations, CHB, Diagnose, GPH, Tumors, disorder of liver (disorder), Therapy, screening, Carcinoma, human hepatitis C virus, Liver, Viral, anatomical protrusion, Surrogate Endpoint, Hepatic disease, Learning, Unspecified disorder of liver, Liver Cell, Biochemical Markers, Procedure, Blood Serum, disease or disorder of liver, Biologic Marker, Diagnoses, Fs(3)Sz11, Liver disorder NOS, Liver disorder in pregnancy unspecified (disorder), Hepatic Cirrhosis, Postmortem, Screenings, Benign, HCC, Marker, Examinations and Diagnoses, unspecified as to episode of care., 3.1.3.48, Diseases, Cirrhosis, Heterologous Insemination, Adult Liver, Dysfunction, Fibrosis, Postmortem Diagnosis, Early, HCV, Liver disorder NOS (disorder), Liver Disease, Carcinomas, Diagnoses and Examination, Postmortem Diagnoses, End Points, death rate, Step, CG11628, Hepatoma, signs, Benign Neoplasms, Infection and Infestation, Striatum-enriched protein-tyrosine phosphatase, Methodological, Immunologic, Laboratory Marker, Methodological Study, Treatments, early, Malignant Neoplasms, disease of liver [Ambiguous], Artificial Insemination, Health, Patient, STEP, Biochemical Marker, spine, Horka, metabolites, CG2684, Fs(3)Horka, [X]Diseases of the liver, Hepatocellular Carcinomas, chronic hepatitis B virus infection, Disorder of liver, liver disorder, HYCC1, Chronic Hepatitis B, Disease Early Detection, LIVER DIS, Liver and Intrahepatic Bile Duct Disorder, GRP1/cytohesin 1, Procedures, Health Resource, Clinical Markers, Peptidomics, Clinical Marker, Neoplasms, post-transfusion hepatitis non A non B virus, Benign Neoplasm, secondary metabolites, Cell Carcinoma, Gene, Dysfunctions, Malignant, AID, Aid, jecur, Surrogate End Points, Intervention or Procedure, protrusion, CG11633, cytohesin/GRP1, Cell Carcinomas, Surrogate Markers, method, Liver Dysfunctions, Liver Cell Carcinomas, sensitive, method used in an experiment, Mass, Studies, Gene Products, Adult Liver Cancer, Screening, DmF2, Antemortem, Metabolomic, liver and intrahepatic bile duct disorder, Technique, sensitivity, Resources, aid, lod, Insemination, Biomarker, study, human hepatitis C virus HCV, liver disorder antepartum, Transfer Learning, Clinical, Liver Cancer, Malignancy, interventionDescription, Biological Marker, l(2)SH2 0323, Liver Cancers, Interventional, Hepatitis B Virus Infection, Diagnoses and Examinations, clinical infection, Study, Neoplasias, Infestation and Infection, Immunologic Markers, unspecified as to episode of care, Neural-specific protein-tyrosine phosphatase, time of survival, HEL-S-284, Clients, Chronic, Hepatic, HIGM2, biological marker, Immunologic Marker, Biologic, Heterologous, Cancer, chronic hepatitis B infection, Antemortem Diagnoses, Intervention Strategies, Disease, data, findings, Malignant Neoplasm, Serum Markers, Proteins, End Point, stepk, Client, chronic, Examination and Diagnoses, Immune Marker, chronic hepatitis B, Human Donor, Early Detection of Disease, development, liver disease, Liver disorder in pregnancy, MT, survival, native protein, Resource, Mass Screenings, Surrogate End Point, liver cirrhosis, Protein, Infection, Neoplasm, A530094C12Rik, Donor, techniques, liver disorder in pregnancy - delivered, l(2)SH0323, Liver Diseases, LD - Liver disease, Biologic Markers, CYH1, Artificial, Intervention, Liver disorder in pregnancy - delivered (disorder), primary cancer, Serum Marker, Adult Liver Cancers, Hepatocellular carcinoma, Surrogate, Arp2, ARP2, Endpoints, with delivery, postnatal growth, metabolite, Cancers, Understanding, Lds, malignant tumor, Surrogate Marker, DmelCG11628, Protein Gene Products, plan specification, Livers, Gene Proteins, Therapeutic, AVIEF, Hepatocellular, Treatment, growth, Serums, Hepatitis C, Neoplasia, methodology, Immune Markers, Hepatitis BfalseSerum proteomic and metabolomic characterization in the progression of chronic hepatitis B-related hepatocellular carcinomaChronic hepatitis B Virus (HBV) infection induces multi-step changes in the liver, involving liver fibrosis, liver cirrhosis (LC) and hepatocellular carcinoma (HCC) which is a deadly malignant tumor that lacks more effective diagnosis and treatment methods. Developing highly sensitive biomarkers could aid in early detection and intervention, improving survival rates. While numerous studies have analyzed HCC and healthy individuals, few have systematically studied HCC biomarkers from the perspective of progression changes. Here, we first constructed a comprehensive HCC-specific candidate biomarker bank, comprising up to 2968 proteins and 103 metabolites, based on the differentially expressed proteins identified by the current study, as well as HCC-related proteins and metabolites summarized from previous studies. We next determined the serum proteomics and metabolomics of 316 healthy controls and patients with HBV, HCV, LC and HCC, and constructed a cancerous trajectory of liver diseases using our DeepPRM targeted method. Based on and the machine learning-based computational pipeline, we found an 8-biomolecular based biomarker combination (accuracy rate: 91.43%) which can be used for the early diagnosis of HCC. Meanwhile, a 12-biomolecular based biomarker combination (accuracy rate: 80.00%) was identified for revealing the alterations in HBV–LC progression. This extensive circulating biomarker development study provides wealthy proteomic and metabolic data resources for better understanding of cancer biology processes in liver diseases.Fri Oct 20 00:00:00 GMT+01:00 2023PXD0462959606